Section 1: Compound Overview (Research Context Only)
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) based on the first 29 amino acids of the native peptide, GHRH(1-29). Four amino acid substitutions distinguish it from the native sequence: Ala2 is replaced to resist dipeptidyl peptidase IV (DPP-IV) cleavage, and additional substitutions at positions 8, 15, and 27 collectively reduce susceptibility to endopeptidase degradation. These modifications produce a peptide with substantially improved proteolytic stability relative to native GHRH(1-29), which carries a half-life measured in minutes under physiological conditions.
The defining structural feature of CJC-1295 with DAC is the Drug Affinity Complex, a maleimide functional group conjugated to the C-terminus of the peptide. This maleimide reacts selectively with the free thiol group at Cys34 on serum albumin via a thiol-maleimide Michael addition, forming a stable covalent thioether bond. Because albumin circulates with a half-life of approximately 19 days and is not filtered by the kidney, this conjugation dramatically extends the effective residence time of the peptide. Pharmacokinetic data from Jetté and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 2005 and 2006, report a terminal half-life of approximately 8 to 10 days for CJC-1295 with DAC in human subjects, compared to the sub-minute half-life of unmodified GHRH(1-29) in plasma.
At the receptor level, CJC-1295 binds the growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor expressed on pituitary somatotrophs. Binding affinity studies in CHO-K1 cells stably expressing human GHRHR demonstrate low-nanomolar EC50 values for cAMP accumulation, placing CJC-1295 in the full agonist category relative to the native ligand. The receptor binding pharmacology is, by current understanding, pharmacologically equivalent to native GHRH in terms of qualitative receptor engagement, with the key distinction being the duration over which receptor occupancy is maintained.
Section 2: Current Research Landscape
The most frequently cited human pharmacokinetic and pharmacodynamic data come from small cohort studies, particularly the work by Jetté et al. involving eleven healthy adult men. In that investigation, a single administration of CJC-1295 with DAC produced measurable elevations in mean 24-hour growth hormone concentration, with reported increases of approximately 50 percent above baseline persisting for more than six days. Serum IGF-1 concentrations followed a broadly parallel trajectory, consistent with downstream GH-axis engagement. Critically, pulsatile GH secretion was preserved across this observation window rather than converted to a tonic secretory pattern, suggesting that prolonged GHRHR occupancy increases GH pulse amplitude without proportionally increasing pulse frequency. This amplitude-dominant modulation is a mechanistically important observation that differentiates the pharmacological behavior of CJC-1295 with DAC from the pattern seen with continuous GHRH infusion paradigms in earlier experimental work.
Despite those early findings, the broader evidence base for CJC-1295 with DAC remains constrained. The primary human pharmacodynamic dataset originates from a single small cohort, and no large-scale placebo-controlled clinical trials have been conducted to characterize the compound’s effects across diverse populations or extended time horizons. Mechanistic questions remain open, including the degree to which prolonged GHRHR occupancy initiates receptor desensitization through GRK-mediated phosphorylation and beta-arrestin recruitment over weeks of sustained albumin-conjugate circulation. In vitro somatotroph desensitization models have not been comprehensively translated to the in vivo context for this specific compound. The physiological significance of amplitude-predominant GH pulse modulation, as distinct from frequency modulation, also warrants further investigation in the context of downstream tissue signaling and IGF-1 regulation. CJC-1295 with DAC carries no approved therapeutic indication and is classified strictly as a research use only compound.
Section 3: Systems Context
Pituitary Somatotroph Gs/cAMP Signaling
GHRHR belongs to the class B (secretin family) GPCR superfamily and couples primarily to the stimulatory G protein Galpha-s upon agonist binding. CJC-1295 engagement of GHRHR initiates Galpha-s dissociation from the heterotrimeric G protein complex, followed by adenylyl cyclase activation and intracellular cAMP accumulation. Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein) at Ser133. Phospho-CREB drives transcriptional activity at the GH gene promoter, increasing GH biosynthesis over sustained timescales. In parallel, cAMP elevation and PKA activity facilitate voltage-gated calcium channel opening, producing intracellular Ca2+ transients that trigger GH-containing secretory granule exocytosis at the somatotroph plasma membrane.
GH/IGF-1 Axis Engagement
Growth hormone secreted from pituitary somatotrophs acts on hepatocytes through GH receptor (GHR), a class I cytokine receptor that signals via the JAK2/STAT5b pathway. STAT5b nuclear translocation drives transcription of IGF-1 (insulin-like growth factor 1), the primary endocrine mediator of many GH-dependent physiological processes. IGF-1 exerts negative feedback on GH secretion through both central (hypothalamic) and pituitary mechanisms. In the context of CJC-1295 research, sustained elevations in circulating IGF-1 observed in the Jetté et al. data are pharmacodynamically downstream of prolonged GHRHR activation and Gs/cAMP pathway engagement, providing a measurable readout for axis activity in study designs.
Somatostatin Counter-Regulation
GH secretion is governed by the interplay between hypothalamic GHRH and somatostatin (SST), the latter acting through Gi-coupled SSTR subtypes on somatotrophs to suppress cAMP accumulation and inhibit GH release. Pulsatile GH secretion in normal physiology reflects reciprocal hypothalamic oscillations in GHRH and SST release. One of the more mechanistically significant observations in CJC-1295 pharmacology is that GH pulsatility is preserved despite sustained GHRHR occupancy, implying that endogenous somatostatinergic counter-regulation continues to modulate secretion episodically even under conditions of prolonged GHRH-receptor engagement. This preservation of pulsatility distinguishes the DAC-conjugate model from continuous GHRH infusion, where tonic secretory suppression of pulsatility has been observed in prior experimental paradigms.
Receptor Desensitization Pharmacology
Prolonged agonist occupancy of GPCRs canonically initiates homologous desensitization through G protein-coupled receptor kinase (GRK) phosphorylation of intracellular receptor domains, followed by beta-arrestin recruitment, receptor uncoupling from Galpha-s, and clathrin-mediated endocytosis. For GHRHR specifically, in vitro evidence from heterologous expression systems confirms that sustained agonist exposure can reduce receptor surface density and cAMP responsiveness over time. Whether the pharmacokinetic profile of CJC-1295 with DAC, maintaining receptor occupancy across days rather than minutes, produces clinically or experimentally meaningful somatotroph desensitization in intact physiological systems remains an open question. Available human data do not definitively resolve this, given the limited study duration and cohort size reported to date.
Albumin-Drug Conjugate Pharmacokinetics
The maleimide-thiol reaction between the DAC functional group and Cys34 on albumin is the central pharmacokinetic determinant for CJC-1295. Albumin’s large hydrodynamic radius prevents glomerular filtration, and its FcRn-mediated recycling in endosomes contributes to its extended plasma persistence. The thioether bond formed between maleimide and the cysteine thiol is stable under physiological pH and temperature conditions, contrasting with the reversible non-covalent binding strategies employed in other albumin-binding peptide platforms. In research settings, this covalent conjugation approach raises questions relevant to peptide synthesis quality, including maleimide hydrolysis during storage, incomplete conjugation efficiency, and the potential presence of unconjugated peptide as a synthesis impurity.
Section 4: Adjacent Research Areas
Areas frequently studied alongside this mechanism in the literature include the comparative pharmacodynamics of shorter-acting GHRH analogs, particularly sermorelin and the modified GHRH(1-29) analog without DAC, which share the same receptor target but exhibit substantially different occupancy durations. Research into GHS-R1a (ghrelin receptor) agonists, including the synthetic compound GHRP-6 and its analogs, frequently appears in the same physiological literature because GHS-R1a signaling on somatotrophs is mechanistically convergent with GHRHR signaling in augmenting GH secretion amplitude, though through distinct receptor systems and intracellular coupling mechanisms. Studies examining the ratio of GH pulse amplitude to pulse frequency as a physiological variable also intersect with CJC-1295 research, given that amplitude modulation appears to be the primary pharmacodynamic signature in available data.
The biochemistry of albumin-drug conjugates more broadly represents a related research domain, with attention to the reactive chemistry of maleimide linkers, hydrolysis kinetics of the succinimide thioether product under different pH conditions, and the pharmacological implications of albumin binding for peptide bioavailability. Researchers working with covalent albumin-binding strategies in peptide design reference the CJC-1295 DAC as one of the earlier examples of this approach applied to hypothalamic releasing factors. Separately, studies of pituitary somatotroph physiology under conditions of GHRHR overactivation, including work on McCune-Albright syndrome where constitutive Galpha-s mutations drive autonomous cAMP production, provide adjacent mechanistic context for understanding the downstream consequences of sustained somatotroph cAMP pathway activation.
Observed Patterns (Non-Clinical Context)
Observed patterns worth noting, but not validated.
Outside of controlled studies, anecdotal reports and informal observations have noted a perceived prolongation in subjective physiological changes following administration of CJC-1295 with DAC, with informal accounts suggesting that whatever effects are observed tend to persist considerably longer than those attributed to shorter-acting GHRH analogs. These informal observations are broadly consistent with the pharmacokinetic rationale of DAC-mediated albumin binding, though consistency, causality, and safety across these accounts cannot be established. Outside of controlled studies, anecdotal reports and informal observations have also noted variability in individual response patterns, with some informal sources describing pronounced differences in apparent magnitude of effect depending on conditions that remain uncharacterized.
These observations carry no clinical validation and should not be interpreted as evidence of efficacy, safety, or predictable outcomes. They are reproduced here solely to document what has circulated in informal research communities. No protocols, dosing recommendations, or compound combinations can be inferred from these accounts, and none are implied here. Researchers evaluating CJC-1295 with DAC in formal settings should rely exclusively on peer-reviewed data and established in vitro or controlled in vivo study designs. Anecdotal patterns do not substitute for controlled experimental evidence and may reflect confounding variables, placebo effects, or entirely unrelated physiological processes.
Section 5: Limitations and Research Boundaries
The translational relevance of existing CJC-1295 with DAC data is constrained by several methodological and biological factors that researchers should treat as central interpretive limitations. The primary human pharmacodynamic dataset is drawn from a single open-label study involving eleven healthy men in a narrow age range, which limits generalizability across sex, age, metabolic state, and baseline somatotroph function. No randomized, placebo-controlled trials have characterized the compound’s pharmacodynamic effects at the population level, and no regulatory body has evaluated it for clinical use. Mechanistic conclusions regarding somatotroph desensitization, GHRHR internalization kinetics, and the long-term consequences of sustained cAMP pathway engagement in intact pituitary tissue remain largely inferential, drawn from in vitro receptor pharmacology data that may not translate directly to in vivo somatotroph biology. The physiological and molecular significance of amplitude-predominant GH pulse modulation, as a distinct phenomenon from frequency modulation, is not fully characterized in terms of downstream tissue-level IGF-1 signaling patterns or receptor sensitivity adaptation.
Researchers working with CJC-1295 with DAC in preclinical or in vitro settings also encounter practical limitations related to peptide synthesis integrity. The maleimide functional group is susceptible to hydrolysis prior to conjugation, which can yield a ring-opened succinamic acid form with reduced reactivity. Incomplete conjugation during synthesis or storage-related degradation can produce heterogeneous peptide preparations in which the proportion of DAC-intact versus DAC-hydrolyzed species is unknown without analytical verification. These synthesis-related variables directly affect the pharmacokinetic behavior of the compound in any experimental system and represent a confounding factor in interpreting study results if preparation quality is not confirmed. Because research outcomes can vary significantly depending on peptide quality and synthesis methods, researchers often prioritize suppliers with transparent third-party testing and batch consistency.
This article is for research and informational purposes only. The compounds discussed are Research Use Only (RUO) and have not received regulatory approval for human use. Nothing in this article constitutes medical advice or endorsement of any substance.